Eli Lilly’s Foundayo gets FDA nod after 12.4% weight loss trial, challenges Novo
FDA has approved Lilly’s oral GLP-1RA Foundayo, whose ATTAIN trial showed 12.4% average weight loss at highest dose, ending Novo Nordisk’s US first-mover advantage. Lilly plans direct-to-consumer launch April 6, before retail pharmacy and telehealth availability.
1. FDA Approval and ATTAIN Trial Results
FDA has approved Lilly’s oral GLP-1RA Foundayo under the CNPV programme, citing the ATTAIN trial where highest-dose patients lost an average of 12.4% body weight. Lilly will launch Foundayo via its direct-to-consumer channel on April 6, with retail pharmacy and telehealth availability soon after.
2. Administration and Manufacturing Benefits
Foundayo can be taken without meal restrictions, improving patient convenience compared with oral Wegovy’s empty-stomach requirement. Its small-molecule structure offers simpler manufacturing and scalability than peptide-based therapies, potentially easing supply chain constraints.
3. Efficacy Comparison and Market Dynamics
While oral Wegovy has demonstrated 2.2% greater weight loss on average, market share competition will hinge on scalability, marketing channels and cash-pay pricing strategies. Lilly’s direct-to-patient approach and manufacturing edge could pressure Wegovy uptake in the US.
4. Implications for Novo Nordisk
Novo’s Wegovy has maintained strong uptake since January, but Lilly’s entry may narrow its US lead and impact revenue growth forecasts. Novo Nordisk may respond with pricing adjustments, expanded distribution or new clinical data to defend its market position.